Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.
Los Angeles Times (LT) - TUESDAY June 8, 1993 Edition: Orange County Edition Section: Business Page: 6 Pt. D Col. 5 Word Count: 237
Michael Flagg; Times Staff Writer
The Irvine concern said it will ask owners of the common stock to approve a 1-for-10 reverse split at the annual meeting in July. That means the 10.5 million shares outstanding at the end of last year would become about 1 million shares, each of which would be valued at 10 times what the old shares cost.
That boost in the price of each share should help Disease Detection meet the requirements for trading on NASDAQ, said the company, which will apply for the listing after the annual meeting. The common stock now trades over the counter.
The company said it will use the $3 million from the sale of the new preferred stock to internationally market its Pro-Step HCG one-step pregnancy test and to market its seven-minute AIDS test, SeroCard-HIV, in South America.
The AIDS test has not yet been cleared for use in the United States, so some of the money will help pay for testing to secure approval from the federal Food and Drug Administration.
Preferred stock is often a more secure investment because it pays a predetermined dividend and its owners get their dividends before holders of common stock.
930608
LT930605
Copyright © 1993 - Los Angeles Times. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Los Angeles Times, Permissions, Times Mirror Square, Los Angeles, CA 90053. http://www.latimes.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .